Abstract:Hypoxia or low oxygen concentration in tumor microenvironment has widespread effects ranging from altered angiogenesis and lymphangiogenesis, tumor metabolism, growth, and therapeutic resistance in different cancer types. A large number of these effects are mediated by the transcription factor hypoxia inducible factor 1⍺ (HIF-1⍺) which is activated by hypoxia. HIF1⍺ induces glycolytic genes and reduces mitochondrial respiration rate in hypoxic tumoral regions through modulation of various cells in tumor microenvironment like cancer-associated fibroblasts. Immune evasion driven by HIF-1⍺ further contributes to enhanced survival of cancer cells. By altering drug target expression, metabolic regulation, and oxygen consumption, hypoxia leads to enhanced growth and survival of cancer cells. Tumor cells in hypoxic conditions thus attain aggressive phenotypes and become resistant to chemo- and radio- therapies resulting in higher mortality. While a number of new therapeutic strategies have succeeded in targeting hypoxia, a significant improvement of these needs a more detailed understanding of the various effects and molecular mechanisms regulated by hypoxia and its effects on modulation of the tumor vasculature. This review focuses on the chief hypoxia-driven molecular mechanisms and their impact on therapeutic resistance in tumors that drive an aggressive phenotype. Impact statement Hypoxia contributes to tumor aggressiveness and promotes growth of many solid tumors that are often resistant to conventional therapies. In order to achieve successful therapeutic strategies targeting different cancer types, it is necessary to understand the molecular mechanisms and signaling pathways that are induced by hypoxia. Aberrant tumor vasculature and alterations in cellular metabolism and drug resistance due to hypoxia further confound this problem. This review focuses on the implications of hypoxia in an inflammatory TME and its impact on the signaling and metabolic pathways regulating growth and progression of cancer, along with changes in lymphangiogenic and angiogenic mechanisms. Finally, the overarching role of hypoxia in mediating therapeutic resistance in cancers is discussed.

HIF-1α: Its Role in Metastasis of Oesophageal Malignancy

HIF-1α pathway: role, regulation and intervention for cancer therapy

Positive Feedback Regulation of Circular RNA Hsa_circ_0000566 and HIF-1α Promotes Osteosarcoma Progression and Glycolysis Metabolism.

HIF-1α signaling: Essential roles in tumorigenesis and implications in targeted therapies

Targeting Hypoxia-Inducible Factor-1-Mediated Metastasis for Cancer Therapy

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics

A Molecular Perspective on HIF-1α and Angiogenic Stimulator Networks and Their Role in Solid Tumors: An Update

Hypoxic tumor microenvironment: Implications for cancer therapy

The role of hypoxic signalling in metastasis: towards translating knowledge of basic biology into novel anti-tumour strategies

Hypoxia: Overview on Hypoxia-Mediated Mechanisms with a Focus on the Role of HIF Genes

Therapeutic Targeting Hypoxia-Inducible Factor (HIF-1) in Cancer: Cutting Gordian Knot of Cancer Cell Metabolism

Central role of hypoxia-inducible factor-1α in metabolic reprogramming of cancer cells: A review

The Role of HIF in Angiogenesis, Lymphangiogenesis, and Tumor Microenvironment in Urological Cancers

Hypoxia: Intriguing Feature in Cancer Cell Biology

Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target

Targeting Hypoxia-Inducible Factor-1 (HIF-1) in Cancer: Emerging Therapeutic Strategies and Pathway Regulation

Hypoxia inducible factor-1ɑ as a potential therapeutic target for osteosarcoma metastasis

Regulating the Expression of HIF-1α or lncRNA: Potential Directions for Cancer Therapy

Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?

Interplay of long non-coding RNAs and HIF-1α: A new dimension to understanding hypoxia-regulated tumor growth and metastasis

Biological function of hypoxia-inducible factor-1α and its relationship with chemotherapy resistance of laryngeal squamous cell carcinoma